Angion Biomedica Corp. Product Forecast - 2015 - PowerPoint PPT Presentation

Loading...

PPT – Angion Biomedica Corp. Product Forecast - 2015 PowerPoint presentation | free to download - id: 7ebd43-YWQzM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Angion Biomedica Corp. Product Forecast - 2015

Description:

Global Markets Directs, Angion Biomedica Corp. Product Pipeline Review - 2015, provides an overview of the Angion Biomedica Corp. s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Angion Biomedica Corp. s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Enquiry @ – PowerPoint PPT presentation

Number of Views:17

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Angion Biomedica Corp. Product Forecast - 2015


1
Angion Biomedical Corp. Product Pipeline Review -
2015
No. Pages 30
Published on October - 2015
2
.
Report Overview
About Angion Biomedica Corp. Product Pipeline
Review 2015 Global Markets Directs, Angion
Biomedica Corp. Product Pipeline Review - 2015,
provides an overview of the Angion Biomedica
Corp.s pharmaceutical research and development
focus. This report provides comprehensive
information on the current therapeutic
developmental pipeline of Angion Biomedica
Corp.s, complete with comparative analysis at
various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of
administration (RoA) and molecule type. It also
reviews latest updates, and featured news and
press releases, along with special features on
late-stage and discontinued projects. Global
Markets Directs report features investigational
drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is
built using data and information sourced from
Global Markets Directs proprietary databases,
Company/University websites, SEC filings,
investor presentations and featured press
releases from company/university sites and
industry-specific third party sources, put
together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/angi
on-biomedica-corp-product-pipeline-review-2015-mar
ket
3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Angion Biomedica Corp.
including business description, key information
and facts, and its locations and subsidiaries The
report reviews current pipeline of Angion
Biomedica Corp.s human therapeutic division and
enlists all their major and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Angion Biomedica Corp.s pipeline
products   Reasons to buy Evaluate Angion
Biomedica Corp.s strategic position with total
access to detailed information on its product
pipeline Assess the growth potential of Angion
Biomedica Corp. in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the Angion Biomedica Corp.s RD
portfolio and develop key strategic initiatives
to reinforce pipeline in those areas Exploit
in-licensing opportunities by identifying windows
of opportunity to fill portfolio gaps
5
Report Overview
  • Develop strategic initiatives by understanding
    the focus areas of Angion Biomedica Corp. and
    exploit collaboration and partnership
    opportunities
  • Identify emerging players with potentially strong
    product portfolio and create effective
    counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by
    identifying the most promising pipeline of Angion
    Biomedica Corp.
  • Develop and design in-licensing and out-licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Explore the dormant and discontinued projects of
    Angion Biomedica Corp. and identify potential
    opportunities in those areas
  • Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4 List of Figures 4 Angion
Biomedica Corp. Snapshot 5 Angion Biomedica Corp.
Overview 5 Key Information 5 Key Facts 5 Angion
Biomedica Corp. - Research and Development
Overview 6 Key Therapeutic Areas 6 Angion
Biomedica Corp. - Pipeline Review 8 Pipeline
Products by Stage of Development 8 Pipeline
Products - Monotherapy 9 Angion Biomedica Corp. -
Pipeline Products Glance 10 Angion Biomedica
Corp. - Early Stage Pipeline Products
10 Preclinical Products/Combination Treatment
Modalities 10
7
Table Of Contents
Discovery Products/Combination Treatment
Modalities 11 Angion Biomedica Corp. - Drug
Profiles 12 NLF-MO 12 Product Description
12 Mechanism of Action 12 RD Progress 12 NLF-NEU
13 Product Description 13 Mechanism of Action
13 RD Progress 13 NLFPD-1233 14 Product
Description 14 Mechanism of Action 14 RD
Progress 14
8
Table Of Contents
OL-1 15 Product Description 15 Mechanism of
Action 15 RD Progress 15 Antisense
Oligonucleotide to Activate Dystrophin for
Duchene Muscular Dystrophy 16 Product Description
16 Mechanism of Action 16 RD Progress
16 Enquiry about this report _at_
http//www.researchbeam.com/angion-biomedica-corp-
product-pipeline-review-2015-market/enquire-about-
report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/angion-biomedica-corp-
product-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com